Aclaris Therapeutics, INC Form 4 insider transactions

Roland Wilhelm Kolbeck, Chief Scientific Officer of Aclaris Therapeutics, Inc., reported multiple transactions in common stock on August 1, 2026.

Aclaris Therapeutics Director Andrew Schiff reported transactions involving common stock, stock options, and restricted stock units.

Aclaris Therapeutics Director Anand Mehra reported transactions involving common stock, including the acquisition of stock options and restricted stock units.

Christopher P. Molineaux, a Director at Aclaris Therapeutics, Inc., reported transactions involving the acquisition of common stock and restricted stock units.

William D. Humphries, a Director at Aclaris Therapeutics, Inc., reported transactions involving the acquisition and disposition of company stock and equity awards.

Vincent Milano, a Director at Aclaris Therapeutics, Inc., reported transactions involving common stock, stock options, and restricted stock units.

Maxine Gowen, a Director at Aclaris Therapeutics, Inc., reported transactions involving the acquisition of common stock and restricted stock units.

Reporting person Braden M. Leonard sold 300,000 shares of Aclaris Therapeutics, Inc. (ACRS) at an average price of $4.53.

Aclaris Therapeutics CEO Neal Walker received substantial restricted stock units and stock options, signaling long-term incentive alignment.

Aclaris Therapeutics, Inc. granted 96,100 restricted stock units and options for 336,300 shares to President and COO Hugh M. Davis, effective February 2, 2026.

Aclaris Therapeutics' Chief Scientific Officer, Roland Wilhelm Kolbeck, received grants of restricted stock units and stock options.

Aclaris Therapeutics' Chief Medical Officer, Jesse Wayne Hall, received significant equity awards including restricted stock units and stock options.

Aclaris Therapeutics' Chief Business Officer, James Loerop, was granted 97,700 Restricted Stock Units and 341,900 Employee Stock Options.

Aclaris Therapeutics' CFO, Kevin Balthaser, received significant equity awards, including restricted stock units and stock options, effective February 2, 2026.

Aclaris Therapeutics' Chief Business Officer, James Loerop, reported the vesting of 20,875 restricted stock units and the subsequent sale of 5,937 shares to cover tax obligations.

Aclaris Therapeutics CEO Neal Walker reported the vesting of 63,475 restricted stock units and the subsequent withholding of 18,611 shares for tax obligations.

Aclaris Therapeutics' President and COO, Hugh M. Davis, converted 18,675 restricted stock units into common stock.

Aclaris Therapeutics' CFO, Kevin Balthaser, acquired 22,025 shares of common stock through the vesting of restricted stock units, with a portion withheld for tax obligations.

Aclaris Therapeutics' Chief Business Officer, James Loerop, filed an amended Form 4 to correct previously reported RSU vesting and tax withholding transactions.

Aclaris Therapeutics' CFO, Kevin Balthaser, reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Aclaris Therapeutics' Chief Business Officer, James Loerop, filed an amended Form 4 to correct the number of shares withheld for tax obligations related to restricted stock unit vesting.

Aclaris Therapeutics' Chief Business Officer, James Loerop, filed an amended Form 4 to correct the number of shares withheld for tax obligations related to restricted stock units.

Aclaris Therapeutics' Chief Business Officer, James Loerop, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations.

Aclaris Therapeutics CEO Neal Walker reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Aclaris Therapeutics' CFO, Kevin Balthaser, reported recent acquisitions of common stock through RSU vesting and subsequent dispositions for tax obligations.

Aclaris Therapeutics' President and COO, Hugh M. Davis, converted 26,750 restricted stock units into common stock on December 2, 2025.

Aclaris Therapeutics' Chief Scientific Officer, Roland Wilhelm Kolbeck, was granted 145,500 Restricted Stock Units and 510,000 stock options, effective August 1, 2025.

Aclaris Therapeutics, Inc. Director Andrew N. Schiff reported the acquisition of new stock options and restricted stock units, alongside the conversion of previously vested restricted stock units into common stock.

Aclaris Therapeutics, Inc. Director Vincent Milano reported the acquisition of new stock options and restricted stock units, alongside the vesting of previously granted restricted stock units, as part of the company's non-employee director compensation policy.

Aclaris Therapeutics, Inc. Director Anand Mehra reported the acquisition of 42,350 stock options and 11,580 restricted stock units, alongside the conversion of 4,793 restricted stock units into common stock.